The latest issue of Hemp Today features an interview with ACI’s Pharmacy Lead, Dr Andy Yates. Andy discusses how the UK’s CBD industry has quietly grown and how the time is right for the government to act to ensure the UK is a world leader in this sector (see page 56).
[Food Navigator] ‘The health benefits are becoming clearer… the future looks very exciting: What’s the CBD sector’s next play?
Many factors have held back CBD as ingredient in mainstream food and drink products. What will the market look like when these challenges recede? Food Navigator catches up with ACI’s Dr Parveen Bhatarah and Laura Williamson.
France 24 reports on Britain’s legal cannabis market which has boomed during the coronavirus pandemic to become the second biggest after the United States, as consumers rushed to alleviate Covid-linked symptoms, industry experts say.
ACI’s Dr Parveen Bhatarah explores explore the future of CBD and other non-psychotropic cannabinoids and cannabimimetics in a co-authored article with Dr Robert Verkerk and Dr Ignazio Garaguso.
Interview with Dr Andy Yates, ACI Pharmacy Associate. Andy has more than 15 years’ pharma experience in medical, commercial, business development and strategy.
Politics.co.uk caught up with ACI co-founder Steve Moore to discuss how UK can lead the world in CBD and cannabis.
Food Navigator look into upcoming innovative CBD products. They highlight results of our recent regulatory successes and market study.
Rainbow’s Cofounder Ludovic Rachou, who is also a founding member of the Association for the Cannabinoid Industry (under the company name Kaya), expressed his trust in the new funding’s ability to get the startup closer to its goal.
Food Manufacturer reports on the opening of our Brussels office to allow us to continue working with partners on the continent to provide bespoke regulatory and compliance services, such as assisting with novel food applications to EFSA and lobbying efforts on behalf of our members within the European institutions.
Following an engaging discussion between three CBD experts brought to you by New Food, they revisit the trio as they answer some of the unanswered questions posed during the session. Featuring Chris Stubbs of GenCanna, Nathan Wogman of Taylor Mammon and ACI’s Shomi Malik.
BBC ran a 6 minute look at the UK CBD market. It features ACI’s Dr Parveen Bhatarah.
It is available on iPlayer and can been seen from 7 mins 17 seconds.
[Nutrition Insight] UK CBD ring trial results brings “invaluable” information for harmonizing a booming market
Speaking to NutritionInsight, Dr. Parveen Bhatarah, regulatory and compliance director for UK’s ACI, discloses that the testing and sharing of different measurement methods will be “invaluable information” for determining the UK industry’s capability in analyzing CBD products.
The UK has the world’s most developed regulatory framework for legal cannabinoids. With a 2021 market estimated to be worth £690 million (€800M) it is the second largest in the world after the US. In this free white paper you’ll learn the requirements to enter this lucrative market.
[Cannabis Industrie] Association for the Cannabinoid Industry (ACI) opent Europees kantoor in Brussel
Dutch – Het stelt de ACI in staat om Europese bedrijven te helpen die de lucratieve Britse markt willen betreden, terwijl ze tegelijkertijd een platform bieden voor samenwerking met de Europese regelgevende instanties.
This European expansion coincides with a further strengthening of the ACI team, adding a wealth of experience in the European legal cannabinoid extract supply chain.
The Association for the Cannabinoid Industry (ACI) has opened a new office in Brussels as the UK-based organization expands its membership offer into the European Union.
Hemp Today takes a closer look at ACI’s new membership offering and explores how we can help business gain access to the lucrative UK market.
Even the coronavirus pandemic couldn’t stop the UK cannabis market to keep growing as a new report claims that the UK has the world’s second largest CBD market behind the US.
With brand new CBD regulations coming into force this year and an array of products hitting the market, Speciality Food put CBD food and drink under the microscope.
Now that the UK regulates CBD as a natural supplement, industry groups are calling on the government to reform contradictory hemp laws
Consumer demand for CBD products has soared during lockdown, according to the Association for the Cannabinoid Industry (ACI), which estimates the sector will generate £690 million in annual sales this year, above a previous forecast of £526 million.
“We were expecting it to grow,” Steve Moore, co-founder and strategic counsel to the CMC and ACI, tells NutritionInsight. “It was always likely that when levels of stress and anxiety would rise with the various lockdowns we’ve had here in the UK, the pandemic would increase demand.”
Sky News reports on our new report and how sales of consumer cannabis products have undergone an “accidental” boom during the pandemic.
Research from two industry pressure groups reveals the UK cannabinoid (CBD) industry was worth £690 million in the 12 months to the end of April – up almost a third year on year.
The UK CBD market could generate £690 million (€800 million) in 2021 sales. More government intervention and investment is needed “to ensure that the UK optimizes ‘Britain’s quiet cannabis revolution’,” ACI’s report urges.
The sector is now estimated to generate £690 million in annual sales for 2021. This figure surpasses predictions made in the seminal market sizing study undertaken by the CMC in 2019 which estimated the market would be worth £526 million in 2021.
The report argues that the market represents a key growth sector for the UK and it is time for the government to adopt a proactive strategy to seize opportunities in the cannabinoids sector. It makes 20 recommendations to stimulate post-Covid economic growth.
The UK CBD sector is predicted to generate £690 million in annual sales in 2021, according to a new report from two leading industry bodies.
The report from the Centre for Medicinal Cannabis (CMC) and the Association for the Cannabinoid Industry (ACI) was published this morning.
CBD brands have had more than a year to sort out their novel food applications, but only three have made the grade so far. The Grocer investigates what’s going on?
As Novel Food regulations for CBD products come into effect, Jersey Hemp speaks to ACI’s External Affairs director Shomi Malik about the importance of robust, relevant scientific data in moving the industry into the mainstream.
The Association for the Cannabinoid Industry (ACI) has publicly refuted the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
CBD industry experts have put together a detailed safety review of THC recommending clear policy recommendations to cut market confusion reports NutraIngredients
Canex cover news of the release of our detailed safety review report on THC.
As outlined in ACI’s report “Health Guidance Levels for THC in CBD products,” the industry group recommend that the UK Home Office enacts a cap of 0.021 mg/kg of THC (and other cannabinol derivatives) per day. This limit would be equivalent to permitting 0.03 percent THC per the recommended 70 mg daily intake of CBD.
ACI member Treehouse Biotech has submitted a Novel Foods application to UK authorities for its Cannabidiol (CBD)-based ingredients in a move that signals the US firm’s intent to capture a slice of the UK’s burgeoning CBD market.
Pharmacy Business Magazine reports that the FSA updated the criteria for CBD products which can remain on sale from 1 April 2021. Previously, only products which were on sale at the time of the FSA’s announcement (13 February 2020) and were linked to an application which had been validated by 31 March 2021 were to be included.
Last February, the Food Standards Agency (FSA) announced that all CBD businesses operating in England and Wales must have a novel foods application “validated” by March 31, 2021, or risk having their CBD oils, drinks, and treats “taken off the shelves.” Now, with just over two weeks left until the deadline, the FSA has clarified that all applications just have to be “submitted” by March 31, 2021.
Coverage from the US publication Hemp Grower on the requirement for novel foods applications to sell CBD products in the UK.
[Cannavist] The Food Standards Agency (FSA) has updated its criteria for CBD products to remain on sale after April 1
Previously, only products that were on sale on February 13, 2020 and linked to an application that had been validated by the March 31, 2021 deadline could continue to be sold.
The criteria for CBD products which can remain on sale from 1 April 2021 has been updated by the Food Standards Agency (FSA).
The FSA has backtracked on its initial expectation for companies to make their novel foods applications at least five weeks in advance of the deadline and confirmed that it will accept applications up until March 31st, after receiving a large number of last minute dossiers.